Daclatasvir-Based Therapy Safety Surveillance in Chinese Patients With Chronic Hepatitis C
Phase of Trial: Phase IV
Latest Information Update: 14 May 2018
Price : $35 *
At a glance
- Drugs Daclatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 02 May 2018 Status changed from not yet recruiting to recruiting.
- 24 Apr 2018 Planned End Date changed from 31 Aug 2021 to 31 Dec 2021.
- 24 Apr 2018 Planned primary completion date changed from 31 Aug 2021 to 31 Dec 2021.